Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Escitalopram oxalate
Drug ID BADD_D00810
Description Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram].[A185420] It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class.[A185726] Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.[A185825,A185726,A185822]
Indications and Usage Labeled indications include major depressive disorder (MDD) and generalized anxiety disorder (GAD). Unlabeled indications include treatment of mild dementia-associated agitation in nonpsychotic patients.
Marketing Status Prescription
ATC Code N06AB10
DrugBank ID DB01175
KEGG ID D02567
MeSH ID D000089983
PubChem ID 146571
TTD Drug ID D08RBC
NDC Product Code 71335-0322; 68071-3265; 55289-828; 43063-761; 71205-313; 55111-944; 58032-0134; 70966-0032; 70934-089; 71052-647; 65862-373; 59746-279; 65372-1143; 68084-617; 68084-618; 65862-411; 0904-6427; 61919-139; 68071-2597; 45562-1130; 59746-280; 71205-168; 65372-1116; 22365-115; 53104-7565; 65862-375; 65015-886; 70934-163; 71205-193; 55154-6893; 70518-1291; 68788-6978; 0456-2021; 65162-019; 13668-136; 17856-0551; 51672-1348; 50090-5112; 65162-020; 65862-374; 0904-6426; 68001-197; 16571-769; 31722-569; 68001-196; 13668-135; 55154-7288; 70934-060; 68554-0007; 71335-0658; 65862-248; 68001-195; 51686-0011; 64220-109; 0456-2006; 0456-2011; 71335-0685; 72761-009; 65162-021; 59746-281; 61919-227; 13668-137; 50090-5131; 55289-768; 63629-8042; 63629-2981; 65691-0066; 70518-0791; 45865-996; 42708-077
Synonyms Escitalopram | Escitalopram Oxalate | Lexapro
Chemical Information
Molecular Formula C22H23FN2O5
CAS Registry Number 219861-08-2
SMILES CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.C(=O)(C(=O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Choreoathetosis17.01.01.003--Not Available
Completed suicide19.12.01.001; 08.04.01.010--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Cough22.02.03.001--
Delirium19.13.02.001--
Delusion19.10.01.001--
Depression19.15.01.001--
Derealisation19.10.02.001--Not Available
Dermatitis23.03.04.002--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diarrhoea07.02.01.001--
Diplopia06.02.06.002; 17.17.01.005--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dry mouth07.06.01.002--
Dysarthria19.19.03.001; 17.02.08.001--
Dyskinesia17.01.02.006--
Dysmenorrhoea21.01.01.002--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dyspnoea22.02.01.004; 02.01.03.002--
Dystonia17.01.03.001--Not Available
Dysuria20.02.02.002--
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.001--Not Available
Ejaculation disorder21.03.01.002--
Electrocardiogram QT prolonged13.14.05.004--
Epistaxis22.04.03.001; 24.07.01.005--
Erythema multiforme23.03.01.003; 10.01.03.015--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 7 Pages